TNF and inflammatory bowel disease: Although the use of anti-TNF agents improves the quality of life of IBD patients by promoting mucosal healing [194], 10–40% of IBD patients do not respond to primary anti-TNF therapy [195–198]; moreover, a subset of responders lose their responsiveness to anti-TNF treatment [199–201].